MDGL supply chain intelligence for Madrigal Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Madrigal Pharmaceuticals, Inc. (MDGL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| F-HOFFMANN-LA-ROCHE-LTD | F-HOFFMANN-LA-ROCHE-LTD | 90% | Madrigal Pharmaceuticals, Inc. (the “Company”), F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, “Roche”) entered into the First Amendment |
| HOFFMANN-LA-ROCHE-INC | HOFFMANN-LA-ROCHE-INC | 90% | Madrigal Pharmaceuticals, Inc. (the “Company”), F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, “Roche”) entered into the First Amendment |
| GYRE | Gyre Therapeutics, Inc. | 72% | Reciprocal relationship from GYRE graph: associated with chronic liver disease (“CLD”) and chronic idiopathic thrombocytopenia (“ITP”). Other Product Candidates F573 is our clinical-stage product can… |
| IVA | Inventiva S.A. | 72% | Reciprocal relationship from IVA graph: Reciprocal relationship from MDGL graph: hase 2 oral DGAT-2 inhibitor. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, … |
| IVA | Inventiva S.A. | 72% | hase 2 oral DGAT-2 inhibitor. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, resulting in lower hepatic triglycerides, reduced lipotoxic fat and decreased inf… |
| NVO | Novo Nordisk A/S | 72% | hase 2 oral DGAT-2 inhibitor. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, resulting in lower hepatic triglycerides, reduced lipotoxic fat and decreased inf… |
| NVO | Novo Nordisk A/S | 72% | Reciprocal relationship from NVO graph: Reciprocal relationship from MDGL graph: Reciprocal relationship from NVO graph: Reciprocal relationship from MDGL graph: hase 2 oral DGAT-2 inhibitor. DGAT-2 … |
| OBDC | Blue Owl Capital Corporation | 72% | Reciprocal relationship from OBDC graph: Reciprocal relationship from MDGL graph: Reciprocal relationship from OBDC graph: Reciprocal relationship from MDGL graph: Reciprocal relationship from OBDC g… |
| ORANY | ORANY | 72% | rice for supply of resmetirom is based on the volume of material subject to a purchase order. The initial term of the Evonik Agreement will expire on December 31, 2029 and will be automatically renew… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from MDGL graph: rice for supply of resmetirom is based on the volume of material subject to a purchase order. The initial term of th… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| HTGC | Hercules Capital, Inc. | 72% | h and development is very expensive, time-consuming and difficult to design and implement and involves uncertain outcomes. Furthermore, the results of preclinical studies and earlier clinical trials … |
| HTGC | Hercules Capital, Inc. | 72% | Reciprocal relationship from HTGC graph: Reciprocal relationship from MDGL graph: h and development is very expensive, time-consuming and difficult to design and implement and involves uncertain outc… |
| IVA | Inventiva S.A. | 72% | Reciprocal relationship from IVA graph: Reciprocal relationship from MDGL graph: Reciprocal relationship from IVA graph: Reciprocal relationship from MDGL graph: Reciprocal relationship from IVA grap… |
| IVA | Inventiva S.A. | 72% | hase 2 oral DGAT-2 inhibitor. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, resulting in lower hepatic triglycerides, reduced lipotoxic fat and decreased inf… |
| NVO | Novo Nordisk A/S | 72% | hase 2 oral DGAT-2 inhibitor. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, resulting in lower hepatic triglycerides, reduced lipotoxic fat and decreased inf… |
| NVO | Novo Nordisk A/S | 72% | Reciprocal relationship from NVO graph: Reciprocal relationship from MDGL graph: Reciprocal relationship from NVO graph: Reciprocal relationship from MDGL graph: Reciprocal relationship from NVO grap… |
| OBDC | Blue Owl Capital Corporation | 72% | wo Phase 1 trials suggested that a single dose of ARO-PNPLA3 reduced liver fat content in homozygous carriers of the PNPLA3 I148M variant, providing proof-of-concept for ARO-PNPLA3 as a precision-med… |
| OBDC | Blue Owl Capital Corporation | 72% | Reciprocal relationship from OBDC graph: Reciprocal relationship from MDGL graph: Reciprocal relationship from OBDC graph: Reciprocal relationship from MDGL graph: Reciprocal relationship from OBDC g… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from MDGL graph: hase 2 oral DGAT-2 inhibitor. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage… |
| ORANY | ORANY | 72% | hase 2 oral DGAT-2 inhibitor. DGAT-2 inhibitors work by blocking the final step in triglyceride assembly and storage, resulting in lower hepatic triglycerides, reduced lipotoxic fat and decreased inf… |
| VKTX | Viking Therapeutics, Inc. | 72% | Reciprocal relationship from VKTX graph: Reciprocal relationship from MDGL graph: Reciprocal relationship from VKTX graph: y a given regulatory authority, such regulatory authority will determine tha… |
| CO-LLC-JEFFERIES-LLC | CO-LLC-JEFFERIES-LLC | 62% | with changes in the prime rate. The First Amendment reduced the interest rate under the Amended Loan Facility to the greater of (i) the prime rate as reported in The Wall Street Journal plus 2.45% an… |
| COMPANY-LLC | COMPANY-LLC | 62% | he year ended December 31, 2023. The increase in interest expense was primarily the result of a higher average outstanding principal balance during the period under the Loan Facility with Hercules. C… |
| COMPANY-LLC-EVERCORE-GROUP | COMPANY-LLC-EVERCORE-GROUP | 62% | with changes in the prime rate. The First Amendment reduced the interest rate under the Amended Loan Facility to the greater of (i) the prime rate as reported in The Wall Street Journal plus 2.45% an… |
| F-HOFFMANN-LA-ROCHE-AG | F-HOFFMANN-LA-ROCHE-AG | 62% | wo Phase 1 trials suggested that a single dose of ARO-PNPLA3 reduced liver fat content in homozygous carriers of the PNPLA3 I148M variant, providing proof-of-concept for ARO-PNPLA3 as a precision-med… |
| LSI-FINANCING-LLC | LSI-FINANCING-LLC | 62% | wo Phase 1 trials suggested that a single dose of ARO-PNPLA3 reduced liver fat content in homozygous carriers of the PNPLA3 I148M variant, providing proof-of-concept for ARO-PNPLA3 as a precision-med… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| MDGL-DEBT-10916 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2022-05-09. |
| MDGL-DEBT | Debt stack $340.8M | 90% | Market cache reports total debt of $340.8M. |
| MDGL-DEBT-10915 | Warrants outstanding: 4555 | 90% | xbrl warrant detail from xbrl 2023-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| MDGL-OWNER-JANUS-HENDERSON-GROUP-PLC | JANUS HENDERSON GROUP PLC | 90% | 13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 384 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ALEC | Alector, Inc. | 100.00 | 2 | |
| KURA | Kura Oncology, Inc. | 100.00 | 2 | |
| IRON | Disc Medicine, Inc. | 100.00 | 2 | |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| ENGN | enGene Therapeutics Inc. | 100.00 | 2 | |
| TGTX | TG Therapeutics, Inc. | 100.00 | 2 | |
| LGND | Ligand Pharmaceuticals Incorporated | 100.00 | 2 | |
| HTGC | Hercules Capital, Inc. | 100.00 | 1 | ['customer'] |
| ALT | Altimmune, Inc. | 100.00 | 2 | |
| GYRE | Gyre Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| CMPS | COMPASS Pathways plc | 100.00 | 2 | |
| DB | Deutsche Bank Aktiengesellschaft | 100.00 | 2 | |
| SVRA | Savara Inc. | 100.00 | 2 | |
| IVA | Inventiva S.A. | 100.00 | 1 | ['customer', 'supplier'] |
| BCYC | Bicycle Therapeutics plc | 100.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 2 | |
| BBIO | BridgeBio Pharma, Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| NVO | Novo Nordisk A/S | 100.00 | 1 | ['customer', 'supplier'] |
| PHGE | BiomX Inc. | 100.00 | 2 |